### ARGENX SE

### CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

	As of December 31,					
(in thousands of \$)	-	2022	ש	2021	)	2020
ASSETS	-	2022	_	2021	_	2020
Non-current assets						
Property, plant and equipment		\$ 16,234	\$	15,844	\$	11,582
Intangible assets		174,901	Ċ	171,684		167,344
Deferred tax asset		79,222		32,191		15,038
Other non-current assets		40,894		54,876		7,816
Research and development incentive receivables		47,488		32,707		20,626
Investment in joint venture		1,323		_		_
Total non-current assets		360,064	_	307,303	_	222,406
Current assets						
Inventories		\$ 228,353	\$	,	\$	25,195
Prepaid expenses		76,022		58,946		27,913
Trade and other receivables		275,697		38,221		6,978
Research and development incentive receivables		1,578		1 002 052		463
Financial assets Cash and cash equivalents		1,391,808 800,740		1,002,052 1,334,676		779,649
Total current assets		2,774,197	-	2,542,971	_	1,216,803 2,057,001
Total current assets	-	2,774,197	_	2,342,971	_	2,057,001
TOTAL ASSETS		\$ 3,134,261	2	2,850,274	\$	2,279,407
TOTAL ASSETS	•	Þ 3,13 <b>4,2</b> 01	ψ	2,030,274	ψ.	2,217,401
				As of		
			Doc	ember 31,		
	_	2022	Dec	2021		2020
(in thousands of \$)	_	2022	_	2021	_	2020
EQUITY AND LIABILITIES Equity						
Equity attributable to owners of the parent						
Share capital	\$	6,640	\$	6,233	\$	5,744
Share premium	Ф	4,309,880	Ф	3,462,775		2,339,033
Translation differences		129,280		131,684		134,732
Accumulated losses		(2,109,791)		(1,400,197)		(991,932)
Other reserves		477,691		333,729		186,474
	\$	2,813,699	Φ	2,534,224	Φ.	1,674,051
Total equity	Φ	2,013,099	φ	2,554,224	Φ.	1,074,031
Non-current liabilities						
Provisions for employee benefits		870		417		156
Lease liabilities		9,009		7,956		6,181
Deferred tax liabilities		8,406		6,438		1,487
Deferred tax habilities  Deferred revenue		0,400		0,436		269,039
Total non-current liabilities	_	18,285	_	14,811	_	276,863
Total non-current natimities		10,205	_	14,011		270,003
Current liabilities						
Lease liabilities		3,417		3,509		3,476
Trade and other payables		295,679		293,415		275,192
Tax liabilities		3,181		4,315		3,497
Deferred revenue		3,161		4,313		46,328
Total current liabilities		302,277		301,239		
Total Cultent Hadmities		304,477		301,239		328,493
Total liabilities	Φ	220 562	Φ	216.050	Φ	(05.25)
Total liabilities	\$	320,562	\$	316,050	\$	605,356
TOTAL FOLLOW AND LIABILITIES	Φ.	2 124 261	Ф	2 950 274	Φ.	270 407
TOTAL EQUITY AND LIABILITIES	\$	3,134,261	\$	2,850,274	<b>\$</b> .	2,279,407

#### ARGENX SE

#### CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

Year Ended December 31, 2022 2020 2021 (in thousands of \$ except for shares and EPS) Product net sales 400,720 \$ Collaboration revenue 10,026 497,277 41,243 Other operating income 34,520 42,141 23,668 Total operating income 445,267 539,418 64,911 Cost of sales (29,431)Research and development expenses (663,366)(580,520)(370,885)Selling, general and administrative expenses (472, 132)(307,644)(171,643)Loss from investment in joint venture (677)Total operating expenses (1,165,607)(888,164)(542,528)**Operating loss** (720,341)(348,746) (477,617)Financial income 27,665 3,633 6,459 Financial expense (3,906)(7,960)(4,578)Exchange losses (50,053)(32,732)(126,234)Loss for the year before taxes (729,314)(399,743) (605,352)\$ Income tax (expense) / benefit 19,720 (8,522)\$ (3,103)Loss for the year (709,594)\$ (408,265)\$ (608,455)Loss for the year attributable to: Owners of the parent (709,594)\$ (408,265) \$ (608,455)Weighted average number of shares 51,075,827 45,410,442 outstanding 54,381,371 Basic and diluted loss per share (in \$) (13.05)(7.99)(13.40)

## ARGENX SE CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME / LOSS

		Year Ended						
	_		D	ecember 31,				
(in thousands of \$ except for shares)		2022		2021		2020		
Loss for the year	\$	(709,594)	\$	(408,265)	\$	(608,455)		
Items that may be reclassified subsequently to profit or								
loss, net of tax								
Currency translation differences, arisen from translating		(2.404)		(2.049)				
foreign activities		(2,404)		(3,048)		_		
Translation effect		_		_		162,273		
Items that will not be reclassified subsequently to profit or								
loss, net of tax								
Fair value gain/(loss) on investments in equity								
instruments designated as at FVTOCI		(18,267)		(39,290)				
Other comprehensive loss, net of income tax		(20,671)	'	(42,338)		162,273		
•		<u> </u>						
Total comprehensive loss attributable to:								
Owners of the parent	\$	(730,266)	\$	(450,603)	\$	(446,182)		

# ARGENX SE CONSOLIDATED STATEMENTS OF CASH FLOWS

	Year Ended December 31,						
(in thousands of \$)		2020					
Operating loss	\$	2022 (720,341)	\$	(348,746)	\$	(477,617)	
Adjustments for non-cash items	Ψ	(120,011)	Ψ	(6 10)/ 10)	Ψ	(177,027)	
Amortization of intangible assets		99,766		776		246	
Depreciation of property, plant and equipment		4,576		5,091		3,671	
Provisions for employee benefits		459		260		76	
Expense recognized in respect of share-based payments		157,026		179,366		96,932	
Fair value gains on financial assets at fair value through							
profit or loss		(4,256)		(11,152)		(2,951)	
Non-cash revenue				(75,000)		_	
Loss from investment in joint venture		677		_		_	
	\$	(462,093)	\$	(249,405)	\$	(379,643)	
Movements in current assets/liabilities							
(Increase)/decrease in trade and other receivables		(222,260)		(31,632)		21,961	
(Increase)/decrease in inventories		(119,277)		(83,880)		(23,852)	
(Increase)/decrease in other current assets		(18,294)		(30,990)		(16,189)	
Increase/(decrease) in trade and other payables		329		134,892		50,537	
Increase/(decrease) in deferred revenue — current		_		(46,327)		(40,441)	
Movements in non-current assets/liabilities							
(Increase)/decrease in other non-current assets		(16,220)		(13,975)		(10,299)	
Increase/(decrease) in deferred revenue — non-current		_		(269,039)		2,655	
Net cash flows used in operating activities		(837,815)		(590,356)		(395,272)	
T		(0.5.1)		(60.4)		(401)	
Interest paid		(851)		(684)		(401)	
Income taxes paid		(24,141)	_	(15,772)		(2,791)	
Net cash flows used in operating activities	\$	(862,807)	\$	(606,812)	\$	(398,463)	
The cush nows used in operating activities	Ψ	(002,007)	Ψ	(000,012)	Ψ	(670,100)	
Purchase of intangible assets		(102,986)		(117,811)		(4,071)	
Purchase of property, plant and equipment		(837)		(3,623)		(1,068)	
(Increase)/decrease in current financial assets		_		(228,239)		341,869	
Purchase of current financial investments (1)	(	1,694,046)				´—	
Sale of current financial investments (1)		1,325,540		_		_	
Interest received		13,146		2,603		7,962	
Investment in joint venture		(2,000)		_		_	
				,			
Net cash flows (used in) / from from investing activities	\$	(461,184)	\$	(347,070)	\$	344,692	
Principal elements of lease payments		(4,165)		(3,855)		(2,550)	
Proceeds from issue of new shares, gross amount		760,953		1,091,326		813,186	
Issue costs paid		(781)		(528)		(613)	
Exchange gain from currency conversion on proceeds from							
issue of new shares		410		966		68	
Payment of employee withholding taxes relating to restricted							
stock unit awards		(5,855)					
Proceeds from exercise of stock options		93,195	_	33,433	_	22,912	
	Φ.	0.42 ===	Φ.	1 101 2 12	φ.	022.002	
Net cash flows from financing activities	\$	843,757	\$	1,121,342	\$	833,003	
In angest/Jeanness ( ) in each and each coninclents	ø	(400 224)	Φ	167.460	Φ	770 222	
Increase/decrease (-) in cash and cash equivalents	\$	(480,234)	\$	167,460	\$	779,232	
Cash and cash equivalents at the beginning of the period	\$	1,334,676	\$	1,216,803	\$	372,162	
Exchange gains/(losses) on cash & cash equivalents	\$	(53,702)	\$	(49,587)	\$	65,409	
Cash and cash equivalents at the end of the period	\$	800,740		1,334,676		1,216,803	
Cash and cash equivalents at the end of the period	Ψ	000,770	ψ	1,007,070	Ψ	1,210,000	

ARGENX SE

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

Attributable to owners of the parent												
Share-ba											Total	_
								pay	yment and		equity	
								_	come tax		attributable	
								de	duction on	Other	to owners	
		Share	Share		Accumulated	T	ranslation	sh	are-based co	mprehensive	of the	Total
(in thousands of \$)		capital	premium		losses	d	ifferences	р	ayments	income	parent	equity
Balance at January 1, 2020	\$	5,209	\$ 1,505,641	\$	(383,477)	\$	(27,541)	\$	80,577 \$	_	\$ 1,180,409	\$ 1,180,409
					(500 AFF)						(500 455)	(600 455)
Loss for the year					(608,455)						(608,455)	(608,455)
Other comprehensive income / (loss)							162,273				162,273	162,273
Total comprehensive income / (loss) for the year					(608,455)		162,273				(446,182)	(446,182)
Income tax benefit from excess tax deductions												
related to share-based payments									8,965		8,965	8,965
Share-based payment									96,932		96,932	96,932
Issue of share capital		468	812,718								813,186	813,186
Transaction costs for equity issue			(613)								(613)	(613)
Exercise of stock options		67	21,287								21,354	21,354
Delance ween anded December 21, 2020	¢.	5 744	¢ 2 220 022	đ	(001 022)	Φ.	124 722	Φ.	10 <i>C</i> 474 ¢		¢ 1 (74 051	¢ 1 (74 051
Balance year ended December 31, 2020	\$	5,744	\$ 2,339,033	\$	(991,932)	<b>3</b>	134,732	\$	186,474 \$	<u> </u>	\$ 1,674,051	\$ 1,674,051
Loss for the year					(408,265)						(408,265)	(408,265)
Other comprehensive income / (loss)					(100,203)		(3,048)			(39,290)	(42,338)	(42,338)
Total comprehensive income / (loss) for the year					(408,265)		(3,048)			(39,290)	(450,603)	(450,603)
Income tax benefit from excess tax deductions					(100,200)		(0,010)			(2),=>0)	(100,000)	(120,002)
related to share-based payments									7,179		7,179	7,179
Share-based payment									179,366		179,366	179,366
Issue of share capital		430	1,090,896						,		1,091,326	1,091,326
Transaction costs for equity issue			(528)								(528)	(528)
Exercise of stock options		59	33,374								33,433	33,433

Balance year ended December 31, 2021	\$ 6,233	\$ 3,462,775	\$ (1,400,197)	\$ 131,684	\$ 373,019 \$	(39,290)	\$ 2,534,224	\$ 2,534,224
Loss for the year			(709,594)				(709,594)	(709,594)
Other comprehensive income / (loss)				(2,404)		(18,267)	(20,671)	(20,671)
Total comprehensive income / (loss) for the year			(709,594)	(2,404)		(18,267)	(730,266)	(730,266)
Income tax benefit from excess tax deductions								
related to share-based payments					3,946		3,946	3,946
Share-based payment					158,282		158,282	158,282
Issue of share capital	294	760,659					760,953	760,953
Transaction costs for equity issue		(781)					(781)	(781)
Exercise of stock options	113	93,082					93,195	93,195
Ordinary shares withheld for payment of								
employees' withholding tax liability		(5,855)					(5,855)	(5,855)
Balance year ended December 31, 2022	\$ 6,640	\$ 4,309,880	\$ (2,109,791)	\$ 129,280	\$ 535,247 \$	(57,557)	\$ 2,813,699	\$ 2,813,699